Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting

Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting

Multiple myeloma (MM) is a cancerous condition characterized by the proliferation of plasma cells within the hematopoietic marrow, resulting in multiple osteolytic lesions. MM patients typically experience bone pain, kidney damage, fatigue due to anemia, and infections. Historically, MM was an incur...

Full description

Bibliographic Details
Main Authors:	Antonio G. Solimando, Markus Krebs, Vanessa Desantis, Donatello Marziliano, Ingrid Catalina Caradonna, Arcangelo Morizio, Antonella Argentiero, Endrit Shahini, Max Bittrich
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Biomedicines
Subjects:	multiple myeloma microenvironment immunotherapy monoclonal antibody
Online Access:	https://www.mdpi.com/2227-9059/11/7/2087

Similar Items

Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
by: Antonio Giovanni Solimando, et al.
Published: (2022-09-01)

Actors on the Scene: Immune Cells in the Myeloma Niche
by: Patrizia Leone, et al.
Published: (2020-10-01)

The role of bone marrow microenvironment in the progression of multiple myeloma from monoclonal gammopathy of undetermined significance
by: A. S. Khudovekova, et al.
Published: (2021-09-01)

Multiple Myeloma: An Update
by: Khalil Al-Farsi
Published: (2013-01-01)

Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma
by: Ilaria Sorgiovanni, et al.
Published: (2025-01-01)

The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease
by: Daniele Derudas, et al.
Published: (2024-08-01)

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
by: Christie P. M. Verkleij, et al.
Published: (2021-03-01)

Will Mass Spectrometry Replace Current Techniques for Both Routine Monitoring and MRD Detection in Multiple Myeloma?
by: Katie L. Thoren
Published: (2021-12-01)

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
by: V. V. Ryzhko, et al.
Published: (2017-11-01)

Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression
by: Ilaria Saltarella, et al.
Published: (2021-11-01)

Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment
by: Gianfranco Lapietra, et al.
Published: (2022-08-01)

Proliferative activity of myeloma cells determined by Ki-67 antibody: Biological and clinical significance
by: Marković Olivera, et al.
Published: (2005-01-01)

Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview
by: Antonella Argentiero, et al.
Published: (2024-03-01)

Editorial: Immunotherapy in Multiple Myeloma
by: Nicola Giuliani, et al.
Published: (2019-08-01)

Coexisting prostate adenocarcinoma with multiple myeloma: A rare case report
by: Yelda Vyas, et al.
Published: (2018-01-01)

A Case of Multiple Myeloma-Associated Systemic Amyloidosis with Multiple Skin Manifestations as the First Symptom
by: Yao S, et al.
Published: (2023-04-01)

Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions
by: Valeria Ferla, et al.
Published: (2024-07-01)

Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies
by: Federico Caroni, et al.
Published: (2025-01-01)

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma
by: Megan Johnstone, et al.
Published: (2022-08-01)

Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study
by: Felipe de Arriba de la Fuente, et al.
Published: (2024-09-01)

Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
by: Panagiotis Samaras, et al.
Published: (2019-04-01)

Multiple Myeloma (Part 1) - Update on Epidemiology, Diagnostic Criteria, Systemic Treatment and Prognosis
by: Alex Guedes, et al.
Published: (2023-07-01)

Coexistence of Light- and Heavy-Chain Deposition Disease and Immunotactoid Glomerulopathy in a Patient with Multiple Myeloma: A Case Report
by: Yaoxian Liang, et al.
Published: (2022-03-01)

Corrigendum: Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
by: Endrit Shahini, et al.
Published: (2023-05-01)

Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
by: Endrit Shahini, et al.
Published: (2022-12-01)

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
by: Jakub Radocha, et al.
Published: (2018-08-01)

The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma
by: Arianna Brevi, et al.
Published: (2022-03-01)

Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma
by: Chandraditya Chakraborty, et al.
Published: (2022-12-01)

Advances in Emerging Therapies for Multiple Myeloma
by: QIAN Chenjing, et al.
Published: (2023-03-01)

Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab
by: Ivan Krečak, et al.
Published: (2023-01-01)

‘Standing on the Shoulders of the Giants’: Dr. Robert Kyle
by: Mohamad Mohty, et al.
Published: (2022-11-01)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Elena Zamagni, et al.
Published: (2020-12-01)

Determination of the target of monoclonal immunoglobulins: a novel diagnostic tool for individualized MGUS therapy, and prevention and therapy of smoldering and multiple myeloma
by: Sylvie Hermouet, et al.
Published: (2023-10-01)

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
by: Philippe Moreau, et al.
Published: (2021-02-01)

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
by: Irene Zamanillo, et al.
Published: (2023-08-01)

Serm Immuno Fixation Electrophoresis as a Diagnostic Method for Monoclonal Gammopathies in Patients with Multiple Myeloma
by: Araz Muhammad Yousif, et al.
Published: (2019-05-01)

Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis
by: Yongjin Zhi, et al.
Published: (2022-12-01)

Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again
by: Federica Plano, et al.
Published: (2023-01-01)

Removal of serological interference in the treatment of multiple myeloma with CD38 monoclonal antibody using polybrene method
by: Yan ZHENG, et al.
Published: (2022-08-01)

Moving Toward Continuous Therapy in Multiple Myeloma
by: Francesca Bonello, et al.
Published: (2019-11-01)